This Form 3 is a routine insider onboarding filing with no trading signal. Monitor future Form 4 filings for any open-market purchases or sales by Bisson, which would carry more actionable information.
Price Chart
Executive Summary
Sabine Bisson, the Chief Operating Officer of Retension Pharmaceuticals, filed a Form 3 initial statement of beneficial ownership, disclosing holdings of stock options and convertible preferred shares. This is a routine administrative filing required upon becoming a Section 16 reporting insider and contains no material financial or operational information.
Key Facts
- Sabine Bisson filed a Form 3 as a new reporting insider (Chief Operating Officer) of Retension Pharmaceuticals.
- Disclosed holdings include options to purchase 24,155 shares at $1.43 (expiring 2034-09-22) and 24,155 shares at $2.43 (expiring 2035-10-30).
- Also holds 1,611 shares of Series A Convertible Preferred Stock and 2,504 shares of Series B Convertible Preferred Stock, each convertible 1:1 into common stock.
- The filing is a standard Section 16(a) initial ownership report with no transactional or market-moving content.
Financial Impact
No financial impact; the filing merely reports pre-existing beneficial ownership with no new transactions.
Risk Factors
- No material risks identified from this filing.
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 3 Filing (Primary) | 0001213900-26-108134 |
| Document: 0001213900-26-108134-index-headers.html | 0001213900-26-108134 |
| Document: 0001213900-26-108134-index.html | 0001213900-26-108134 |
| Document: 0001213900-26-108134.txt | 0001213900-26-108134 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 3d ago | 8-K | $16.55 | awaiting T+5 | — | $14.55 (−12.11%) |
Oct 16, 2026 9d ago | SC 13G | $16.33 | awaiting T+5 | — | $14.55 (−10.93%) |
Oct 16, 2026 10d ago | SC 13G | $14.07 $15.25 | ▲ +8.39% | ▲ +8.82% | $14.55 (+3.38%) |
Oct 15, 2026 11d ago | SC 13G | $12.21 $15.50 | ▲ +26.95% | ▲ +27.96% | $14.55 (+19.12%) |
Oct 14, 2026 11d ago | SC 13D | $12.21 $15.50 | ▲ +26.95% | ▲ +27.96% | $14.55 (+19.12%) |
Oct 13, 2026 12d ago | Insider Cluster | $11.64 $15.00 | ▲ +28.87% | ▲ +28.41% | $14.55 (+24.96%) |
Oct 13, 2026 12d ago | 3 | $11.64 $15.00 | ▲ +28.87% | ▲ +28.41% | $14.55 (+24.96%) |
Oct 9, 2026 16d ago | 424B4 | $11.32 $16.33 | ▲ +44.26% | ▲ +45.75% | $14.55 (+28.49%) |
Oct 9, 2026 17d ago | EFFECT | $10.53 $14.07 | ▲ +33.62% | ▲ +35.59% | $14.55 (+38.13%) |
Oct 8, 2026 17d ago | 3 | $10.53 $14.07 | ▲ +33.62% | ▲ +35.59% | $14.55 (+38.13%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers